摘要
目的探讨乳腺癌患者新辅助化疗预后影响因素。方法回顾性分析2010年4月至2014年4月在昆山市第二人民医院乳腺外科住院进行新辅助化疗治疗的80例乳腺癌患者的临床病理资料。结果单因素分析显示,不同年龄、TNM分期、雌激素受体(ER)表达、孕激素受体(PR)表达、人表皮生长因子受体2(HER-2)表达、淋巴结转移枚数、新辅助化疗(NAC)方案、疗效评价,新辅助化疗乳腺癌患者的无病生存率均有统计学意义(均P<0.05),不同年龄、TNM分期、ER表达、PR表达、HER-2表达、淋巴结转移枚数、疗效评价,新辅助化疗乳腺癌患者的总生存率均有统计学意义(均P<0.05),未发现不同NAC治疗周期、手术方式、术后有无放疗对新辅助化疗乳腺癌患者的无病生存率和总生存率有统计学意义(均P>0.05)。多因素分析显示,TNM分期、ER表达、HER-2表达、疗效评价均为新辅助化疗乳腺癌患者无病生存时间及总生存时间的独立预后因素,差异均有统计学意义(均P<0.05)。结论 TNM分期、ER表达、HER-2表达、疗效评价为新辅助化疗乳腺癌患者预后的影响因素。
Objective To explore the influence factors of prognosis in 80 cases of breast cancer patients with neoadjuvant chemotherapy. Methods Selected 80 cases of breast cancer patients with neoadjuvant chemotherapy in our hospital Breast surgery from April 2010 to April 2014,then collected and analyzed the clinical and pathological data. Results The single factor analysis showed that there were significant differences in disease-free survival among patients with different age,TNM stage,ER expression,PR expression,HER-2 expression,lymph node metastasis,NAC,efficacy evaluation（ P〈0. 05）,different age,TNM stage,ER expression,PR expression,HER-2 expression,lymph node metastasis number,efficacy evaluation,new adjuvant chemotherapy had statistically differences with breast cancer patients＇ overall survival rates（ P〈0. 05）,there was no difference in the disease-free survival and overall survival of breast cancer patients with different NAC cycles,the way of operation,with or not with neoadjuvant chemotherapy（ P〈0. 05）. Multivariate analysis showed that TNM stage,ER expression,HER-2 expression and efficacy evaluation were independent prognostic factors for disease-free survival and overall survival in breast cancer patients with neoadjuvant chemotherapy（ P〈0. 05）. Conclusion TNM staging,ER expression,HER-2 expression,and efficacy evaluation are the influencing factors for the prognosis of breast cancer patients with neoadjuvant chemotherapy.
出处
《中国肿瘤临床与康复》
2016年第8期921-924,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
乳腺肿瘤
新辅助化疗
预后
影响因素
Breast neoplasms
Neoadjuvant chemotherapy
Prognosis
Influence factors
